The Mechanism of Preventive Effect of Captopril on Renal Ischemia Reperfusion Injury is Independent of ATP Dependent Potassium Channels

Rouhollah Habibey¹, Marjan Ajami², Ali Hesami³ and Hamidreza Pazoki-Toroudi*¹

¹Dept. of Physiology and ²Dept. of Nutrition, Iran University of Medical Sciences and ³Dept. of Pathology, Milad Hospital, Tehran, Iran

Received 11 November 2007; revised 4 February 2008; accepted 16 March 2008

ABSTRACT

Background: Renal ischemia reperfusion (IR) injury has been a major source of concern during the past decades and angiotensin converting enzyme (ACE) inhibitors have been successfully used to prevent this injury. There have been some controversial reports about the involvement of K<sub>ATP</sub> channels in the mechanism of action of ACE inhibitors. In this study, we examined the effect of K<sub>ATP</sub> channel blocker (Glibenclamide) on preventive effect of captopril on renal IR injury. Methods: Male sprague-dawley rats were pretreated with glibenclamide (1, 5 and 25 mg/kg) and/or captopril (5 mg/kg). They were anesthetized using ketamine (50 mg/kg) and xylazine (10 mg/kg). The left flank was incised and the left renal artery was clamped for 30 minutes. After that, the kidney was reperfused for 2 hours and then the animal was killed. The Right and left kidneys were removed and evaluated for microscopic damage. Results: Captopril reduced renal IR injury while glibenclamide by itself caused no change. Glibenclamide did not change the preventive effect of captopril. Conclusion: It seems that the preventive effect of captopril is not directly mediated by K<sub>ATP</sub> channels and further attention should be paid to other receptor-mediated angiotensin II effects.

Keywords: Angiotensin converting enzyme (ACE) inhibitors, Angiotensin II, Captopril, Glibenclamide, K<sub>ATP</sub> channels

INTRODUCTION

Reperfusion is known to produce ischemic and hypoxic lesions in vivo and in vitro in different organs [1]. Several factors have been implicated in the pathophysiological changes of ischemia reperfusion (IR) injury [2]. There has been great interest in the role of renin angiotensin system and in particular angiotensin II (Ang II) in cardiovascular and renal physiology and pathology. Until the last decade, this interest was directed only towards the haemodynamic effect of angiotensin as a vasopeptide [3]. The discovery of angiotensin converting enzyme (ACE) inhibitors added a new dimension to our understanding of non-homodynamic effects of Ang II [4-6]. Captopril, a ACE inhibitor, has been successfully used in protecting against IR induced renal injury.

In general, Ang II stimulation facilitates the protein kinase C (PKC) activation. The involvement of PKC pathway for the regulation of K<sub>ATP</sub> channels, however, remained controversial [7-11]. K<sub>ATP</sub> Channels [12] activate and serve as metaboelectrical sensors, thereby regulate the duration of action potential, Ca<sup>2+</sup> influx, and myocardial contractility [13]. The activation of the channels minimizes the infarct size in several animal models [14]. K<sub>ATP</sub> channel regulation of vasoactivity in vascular beds, including the renal medulla, has been examined by testing the ability of glibenclamide to lower blood flow. Gardiner and colleagues [15] found that glibenclamide infusion into rats induced renal vasoconstriction. In the kidney, a role for modulation of arteriolar tone by K<sub>ATP</sub> channels has...
been repeatedly observed [16, 17]. There have been some controversial reports about the involvement of K_{ATP} channels in the mechanism of action of ACE inhibitors. Some believe that ACE inhibitors’ mechanism of action is mediated by K_{ATP} channels [18] while others disagree with this concept [19]. In this study, we examined the effect of captopril on renal IR injury in the presence and absence of glibenclamide (K_{ATP} channel blocker).

**MATERIALS AND METHODS**

**Animals.** Male sprague-dawley rats weighting 150 to 200 grams with free access to food and water, were divided into 9 groups each containing 7 rats (Table 1). Animals were pretreated with intraperitoneal glibenclamide (1, 5 and 25 mg/kg) 2 hours before surgical procedure and/or subcutaneous captopril (5 mg/kg) one hour before surgical procedure. We measured blood pressure in all groups before ischemia.

**Surgical procedure.** The surgical procedure was based on two kidneys one clamped (2K1C) model. Animals were anesthetized using xylazine (10 mg/kg) and ketamine hydrochloride (50 mg/kg) intraperitoneally. In sham operation group, the left flank was incised and then closed without any further manipulation. In other groups, the left flank was incised and the left renal artery was exposed. Then, it was clamped using an arterial clamp (Ischemic phase). The skin was temporarily closed and animal was kept in a suitable warm environment. After 30 minutes of ischemia, the arterial clamp was removed and the skin was closed (Reperfusion phase). Two hours later, animal was killed and both kidneys were removed and fixed in 10% formalin.

**Study groups.** Animals were randomly assigned to one of the following groups of 7 rats each. Group I was the control group (sham operated). Group II received normal saline by the subcutaneous route 2 hours before the occlusion of renal artery. Group III received 5 mg/kg captopril, groups IV, V and VI received glibenclamide 1, 5 and 25 mg/kg, respectively before IR and groups VII, VIII and IX received glibenclamide 1, 5 and 25 mg/kg, respectively before pretreatment with captopril 5 mg/kg and then IR was induced.

**Pathological evaluation.** The samples were stained using H and E technique and evaluated for microscopic damage. The left kidney was compared to the right kidney (control) and reperfusion injury was graded based on its severity as follow: 0, No damage seen; 1, Necrosis of individual cells; 2, Necrosis of all adjacent proximal convoluted tubules, with survival of surrounding tubules; 3, Necrosis confined to the distal third of the proximal convoluted tubules with a band of necrosis extending into the inner cortex; 4, Necrosis affecting all the three segments of the proximal convoluted tubules [20].

**Drugs.** Captopril was purchased from Quimica Sintetica, S.A., Spain. Glibenclamide was purchased from Tehran-Darou Pharm. Co., Iran. Xylazine and Ketamine hydrochloride were purchased from Alfason-Woerden, Holland.

**Table 1.** Grading the effects of different doses of captopril and glibenclamide on ischemia reperfusion-induced renal injury in rats.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Grading the Histological severity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>I</td>
<td>Saline + SO</td>
<td>7</td>
</tr>
<tr>
<td>II</td>
<td>Saline + IR&lt;sup&gt;S&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>III</td>
<td>Capto 5 mg/kg + IR&lt;sup&gt;S&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>IV</td>
<td>Gli 1 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>V</td>
<td>Gli 5 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>VI</td>
<td>Gli 25 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>VII</td>
<td>Gli 1 mg/kg + Capto 5 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>VIII</td>
<td>Gli 5 mg/kg + Capto 5 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
<tr>
<td>IX</td>
<td>Gli 25 mg/kg + Capto 5 mg/kg + IR&lt;sup:NS&lt;/sup&gt;</td>
<td>0</td>
</tr>
</tbody>
</table>

SO, sham operation; IR, ischemia reperfusion; Capto, captopril; Gli, glibenclamide; S, significant difference; NS, non-significant difference. Group II was compared to group I. Groups III, IV, V, VI were compared to group II. Groups VII, VIII, IX were compared to group III.
Statistical evaluation. Mann-Whitney mean rank test was used to assess the significance of differences between treated groups. Differences among groups were considered significant at \( P \) value of \( \leq 0.05 \). Calculations were performed using the SPSS 14 statistical package.

RESULTS

Subcutaneous injection of saline and subsequent sham operation caused no renal injury. Saline and subsequent ischemia and reperfusion caused renal injury with pathologic grades of 3 and 4. Captopril (5 mg/kg) reduced the IR injury to grade 1 and this reduction was statistically significant \((P<0.05)\) compared to IR group. Glibenclamide itself (1, 5 and 25 mg/kg) could not change the grading of renal injury, while pretreatment with glibenclamide (1, 5 and 25 mg/kg) caused no change in protective effect of captopril (Table 1). Indeed, we have not seen any change in blood pressure of studied rats.

DISCUSSION

In this study, we found out that IR caused severe renal injury and captopril was able to prevent this damage. Ang II is a potent vasoconstrictor, known to activate channels that depolarize vascular smooth muscle and allow \( Ca^{2+} \) entry. Its effects in reducing the activity of \( K^+ \) channels should enhance its action in causing membrane depolarization, and so contribute to its vasoconstrictor action, since voltage-activated \( Ca^{2+} \) channels, and so \( Ca^{2+} \) entry are highly sensitive to small changes in membrane potential. Further, it is clear that the activity of such channels contributes to resting blood flow in a number of vascular beds including those of the coronary, mesenteric, skeletal muscle and renal circulations, since glibenclamide increases resistance to blood flow in those tissues. Since \( K_{ATP} \) channel activity is increased by a number of vasodilators and by metabolic stress such as hypoxia, the potential for inhibition by Ang II to reduce \( K^+ \) conductance should also be increased under such conditions. Thus, the action of Ang II in inhibiting \( K_{ATP} \) channels via activation of PKC described here may make an important contribution to the vasoconstrictor action of the peptide [18, 21].

Antagonization of Ang II action by ACE inhibitors improves the symptoms of congestive heart failure and reduces reperfusion injury and arrhythmias [22-24]. Using the rat model, Linz et al demonstrated that ACE inhibitors reduce both ischemic areas at risk and zones of infarcted muscle. The inhibitory pathway of \( K_{ATP} \) may be one of several actions of Ang II and in part account for the cardioprotective and renoprotective actions of ACE inhibitors [25-27].

There have been some controversial reports that ACE inhibitors’ mechanism of action is/isn’t mediated by \( K_{ATP} \) channels [18, 19]. The results of this study showed that the protective effect of captopril (ACE inhibitor) is not affected by glibenclamide (\( K_{ATP} \) channel blocker). One might propose that the protective effect of captopril is not mediated by \( K_{ATP} \) channels but some data suggest that there might be some sort of relationship between these two. Sargent et al have indicated that SH containing ACE inhibitors (captopril like) show an effect on \( K_{ATP} \) channel open probability in vascular smooth muscle but Koppel et al. [19] showed that there is little or no effect on \( K_{ATP} \) channels due to the presence of SH branch. This protective effect of captopril did not change in the presence of glibenclamide (inhibitor \( K_{ATP} \) channel). From our experiments, we conclude that the postulated opening of \( K_{ATP} \) channels by SH-group-containing ACE inhibitors contributes to the vasodilation of vascular/microvascular kidney caused by ACE inhibitors, and that SH groups have no influence upon \( K_{ATP} \) channels of vascular/microvascular kidney. Also, our recent study showed that ACE inhibitor was able to attenuate kidney IR injury and this preventive effect may be independent of Ang II AT1 receptors [28]. It seems logical to expect some kind of relationship between ACE inhibitors and \( K_{ATP} \) channels. Our study indicates that no direct relationship exists between these two but further exploration focused on other mechanisms of Ang II receptor-mediated function might be the answer to this mystery.

ACKNOWLEDGMENTS

The authors highly appreciate the Iran University of Medical Sciences (Tehran, Iran) for research grant P6, which supported this work.

REFERENCES


27. Yatsu, T., Aoki, M., Uchida, W. and Inagaki, O.